Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 18/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 9/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 8/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19826988 | 0.90 | NTRK1 (0.47) | NTRK1NTRK3NTRK2TGFBR1KDM4E | |
| SCHEMBL19816830 | 0.88 | NTRK1 (0.51) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16946698 | 0.88 | NTRK1 (0.52) | NTRK1NTRK3NTRK2 | |
| SCHEMBL27060264 | 0.88 | NTRK1 (0.50) | NTRK1NTRK3NTRK2TGFBR1 | |
| SCHEMBL29511282 | 0.88 | NTRK1 (0.52) | NTRK1NTRK3NTRK2 | |
| SCHEMBL29511254 | 0.88 | NTRK1 (0.52) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16946773 | 0.88 | NTRK1 (0.52) | NTRK1NTRK3NTRK2 | |
| SCHEMBL18361539 | 0.87 | NTRK1 (0.47) | NTRK1NTRK3NTRK2TGFBR1 | |
| SCHEMBL18361533 | 0.83 | NTRK1 (0.46) | NTRK1NTRK3NTRK2TGFBR1 | |
| SCHEMBL19826941 | 0.82 | NTRK1 (0.39) | NTRK1NTRK3NTRK2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689400-B2 | Macrocycle kinase inhibitors | Turning Point Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190169208-A1 | MACROCYCLE KINASE INHIBITORS | TP THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169208-A1 | MACROCYCLE KINASE INHIBITORS | DCK, MAP3K20, PLK1 | NTRK1 964/4885NTRK3 790/4885NTRK2 1605/4885 |
| US-10689400-B2 | Macrocycle kinase inhibitors | DCK, MAP3K20, PLK1 | NTRK1 964/4885NTRK3 790/4885NTRK2 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.